APOL1 gene test study for trial volunteers
Part of Kidney & urinary clinical trials.
This study checks if a new genetic test for the APOL1 gene works correctly. It uses samples from people who have already joined another drug trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be taking part in a separate drug company clinical trial for kidney disease.
- You have signed the consent form for this genetic testing study.
- A doctor or trial staff will send your blood or tissue sample to the testing lab.
- The sample must be in good condition and the right amount for testing.
- You are not excluded from the main drug trial based on its own rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic markers (genes) related to kidney risk in Black/African American adults. It may help researchers better understand who is at higher risk and how genetics could guide future care.
This trial tests an experimental drug called MZE829 for people with kidney disease linked to the APOL1 gene. It aims to see if the drug can help protect kidney function.
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
This study uses a new blood test to find and monitor people with APDS, a rare immune disease, who may be helped by the drug leniolisib. It aims to improve how doctors screen and track treatment response.
This study tests a new medicine called AP303 for people with type 2 diabetes and chronic kidney disease. The goal is to see if it is safe and how the body processes it. If you have diabetes and your kidneys are not working as well as they used to, this trial might help find new treatment options.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
Hear when a new APOL1-mediated Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.